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Abstract: A growing number of genetic neurodevelopmental disorders are known to be associated
with unique genomic DNA methylation patterns, called episignatures, which are detectable in
peripheral blood. The intellectual developmental disorder, X-linked, syndromic, Armfield type
(MRXSA) is caused by missense variants in FAM50A. Functional studies revealed the pathogenesis to
be a spliceosomopathy that is characterized by atypical mRNA processing during development. In
this study, we assessed the peripheral blood specimens in a cohort of individuals with MRXSA and
detected a unique and highly specific DNA methylation episignature associated with this disorder.
We used this episignature to construct a support vector machine model capable of sensitive and
specific identification of individuals with pathogenic variants in FAM50A. This study contributes
to the expanding number of genetic neurodevelopmental disorders with defined DNA methylation
episignatures, provides an additional understanding of the associated molecular mechanisms, and
further enhances our ability to diagnose patients with rare disorders.
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1. Introduction
Mendelian neurodevelopmental disorders usually present with developmental delay
(DD), intellectual disability (ID), and/or congenital anomalies (CA). These syndromes are
often associated with complex and overlapping symptoms including overgrowth, aberrant
craniofacial features, seizure, and neurological abnormalities, which may complicate clinical
diagnosis [1]. The frequency of Mendelian disorders is approximated to be 40 to 82 per 1000
live births [2]. Considering all congenital anomalies, 8% of individuals are estimated to have
a genetic disorder before adulthood [3]. Given the broad range of genetic and phenotypic
heterogeneity, based on an individual’s presentation and clinical assessment alone, it is often
impossible to determine the precise clinical diagnosis in the absence of a specific molecular
genetic diagnosis. Conventional genetic testing, including the analysis of sequence and copy
number variants (CNVs) and comprehensive genome-wide methods such as whole exome
sequencing (WES), leaves a substantial proportion of subjects unresolved [4]. Genetic analysis
in patients with a confirmed clinical diagnosis often yields no significant genetic findings or
results in genetic variants of unknown clinical significance (VUS).
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Epigenetics is defined as the study of heritable alterations in DNA that do not involve
the DNA sequence. Recent advances in epigenetic analysis have provided an alternate
approach for diagnosis of genetic disorders. Pathogenic variants in genes that encode
proteins involved in the epigenetic machinery, chromatin assembly and transcription regulation can cause changes in the genome-wide pattern of DNA methylation, differentiating
them from unaffected individuals [5]. These highly sensitive and specific changes in DNA
methylation patterns, referred to as episignatures, are currently used to help reclassify
VUS’s as likely pathogenic or benign, thus enabling a definitive diagnosis [6]. Hence, a
term episignature is used to describe a consequence of a unique DNA methylation pattern,
resulting from the underlaying DNA mutation.
Episignatures have the potential to provide insights into the functional effects of DNA
methylation variation and its association with pathophysiology of a disorder. We and
others have demonstrated the utility of episignatures in diagnosing rare genetic disorders.
More than 30 different genetic syndromes associated with mutations in over 50 genes
have been described that exhibit specific DNA methylation episignatures [7–16]. These
episignatures can overlap. For instance, CpG sites located in HOXA5 were reported to be
similarly hypermethylated in CHARGE and Kabuki syndromes [9]. At one extreme, DNA
methylation episignatures can be identical across multiple genes belonging to common
protein complexes. As an example, Coffin–Siris syndromes (CSS), Nicolaides–Baraitser syndrome (NCBRS), and Chr6q25 microdeletion syndrome, commonly known as BAFopathies,
which arise from SWI/SNF remodeling complex defects, share a common, highly overlapping episignature. Interestingly, the overlap between the methylation pattern of some
subtypes of CSS and NCBRS are higher than the overlaps found within some CSS subtypes [17]. At the other extreme, we have identified multiple distinct episignatures in
single genes. Patients with ADNP syndrome exhibit two distinct DNA methylation profiles
associated with two separate protein domains [18]. These genome wide episignatures are
the consequence of genetic mutations resulting in a defective function of the related protein.
Regions with significant disruptions in DNA methylation can range from hundreds to tens
of thousands of probes in the methylation array, but can show partial overlap between
different disorders, and normally do not involve disruption of DNA methylation in the
related gene [19].
The intellectual developmental disorder, X-linked, syndromic, Armfield type (MRXSA)
is a rare genetic disorder, described first in 1999 [20]. Patients inherit this syndrome in an
X-linked recessive fashion. Affected males manifest symptoms including intellectual, skeletal,
ocular, and craniofacial abnormalities, while carrier females have no clinical symptoms. In
infancy to early childhood, patients represent seizures [20]. All individuals exhibit a degree of
global developmental delay, presenting with impaired speech, difficulty in walking, and/or
a need for special education. The skeletal abnormalities include short stature, small hands
and/or feet, joint hypermobility, stiff joints, and/or club foot. Most patients have ocular
anomalies, such as glaucoma, strabismus, nystagmus, exotropia, and/or keratoconus. The
craniofacial abnormalities include macrocephaly, epicanthal folds, depressed nasal bridge,
downslanted palpebral fissures, cleft palate, bow-shaped mouth, microretrognathia, broad
forehead, micrognathia, infraorbital creases, wide nasal root, short and lightly upturned nose
with underdeveloped nares, posteriorly rotated ears, faint hemangiomas between brows and
at back of neck, bulbous nose, prominent tall forehead, and/or overfolded helices [20,21].
Armfield et al. attributed the condition to an 8 Mb region on Xq28, using linkage analysis [20].
Recently, rare hypomorphic missense variants in FAM50A (family with sequence similarity
50 member A) have been identified as the causal variants for the disorder in this region
(Xq28) [21]. Defects in FAM50A are established to cause aberrant spliceosome C complex
function, defining MRXSA as a spliceosomopathy [21].
In this study, we performed genome-wide DNA methylation analysis to assess if an
episignature was associated with MRXSA. By comparing the methylation data of patients
with matched normal controls, a specific DNA methylation profile was identified. Using
these data, we developed a support vector machine (SVM) classifier for this disorder.
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This classifier enables the identification of individuals with likely pathogenic variants
in FAM50A. We also demonstrated the high specificity of the FAM50A episignature by
comparing it to over 1000 samples from patients with episignatures in over 40 genes
associated with 38 other neurodevelopmental syndromes.
2. Materials and Methods
2.1. Subjects and Cohorts
DNA samples were extracted from peripheral blood of six individuals from three
different families with a confirmed diagnosis of MRXSA, all recruited from the Greenwood
Genetic Center (Greenwood, SC, USA). For one of the patients, two samples were available,
extracted at different ages. The newer sample was used for the purpose of selecting the
significant probes and training the classification model, and the older sample was used as
a technical control sample. All the samples and records were de-identified. The research
was conducted in accordance with the Declaration of Helsinki. The study protocol was
approved by the Western University Research Ethics Board (REB 106302; REB 116108).
Physicians obtained informed consent from the aforementioned patients for use of the
clinical information.
2.2. Methylation Data Analysis
We performed DNA methylation analysis of the samples after bisulfite conversion, using Illumina Infinium methylation EPIC bead chip arrays, according to the manufacturer’s
protocol. These arrays include over 850,000 CpG sites in the human genome. Details of
the methylation data analysis are previously described [4,8,19]. In summary, intensity data
files comprising the methylated and unmethylated signal intensities were analyzed in R
4.0.2. We normalized the methylation data based on the Illumina normalization method
with background correction using the minfi package [22]. We eliminated the following
probes: Detection p-value > 0.01; X and Y chromosome probes; contained single nucleotide
polymorphisms (SNPs) at or near CpG interrogation sites; or cross-reactive with other
genomic regions. The removal of these probes is performed in order to ensure that the
difference observed between the case and control groups is only due to DNA methylation
changes rather than other factors. Using the MatchIt R package [23], for each case we
selected seven controls matched for age, sex, and array type from the EpiSign Knowledge
Database (EKD) [19]. The number of control samples was increased until the matching
quality reached an optimum point, and the ratio of seven to one proved to be the most
appropriate choice. Principal component analysis (PCA) was used to check for outlier case
and control subjects and examine the batch effect.
2.3. Probe Selection, Dimension Reduction, and Constructing a Supervised Classifier
Methylation levels calculated as the ratio of methylated signal intensity over the sum of
methylated and unmethylated signal intensities, called the β-values, were converted to Mvalues by logit transformation using the formula log2 (β/(1-β)) to obtain homoscedasticity for
linear regression modeling using the limma package [24]. The model matrix was constructed
by these values. We added as confounding variables the estimated blood cell proportions
derived by the algorithm developed by Houseman et al. [25]. Next, eBayes function was
operated in order to moderate the generated p-values. We performed the probe selection
process in three steps. First, we selected 1000 probes with the highest product of methylation
differences between case and control samples and the negative of the logarithm of multipletesting corrected p-values derived from the linear modeling by Benjamini–Hochberg (BH)
method. The advantage of this approach over setting strict cut-off values for the p-value and
methylation difference is that the interaction between these values is considered and one can
compensate for the other, ensuring that the most significant probes are selected. Subsequently,
we performed a receiver’s operating characteristic (ROC) curve analysis and retained 500
probes with the highest area under the ROC curve (AUC). Finally, we eliminated probes with
a pair-wise correlation greater than 0.95 measured using Pearson’s correlation coefficients

Int. J. Mol. Sci. 2021, 22, 1111

4 of 13

for all probes, for the case and control samples separately. We then performed hierarchical
clustering using the remaining 175 probes, by Ward’s method on Euclidean distance using
the gplots package. More details about the 175 selected probes are summarized in Table S2.
The methylation levels (β values) at those probes for Patients 1–6 and for the control samples
have also been provided in Table S3. Multidimensional scaling (MDS) was done by scaling
of the pair-wise Euclidean distances between samples. We constructed a binary support
vector machine (SVM) using the e1071 package as described previously [4,8,19]. In order
to detect the differentially methylated regions (DMRs), we used the DMRcate package [26],
and regions containing at least 5 different CpGs within 1kb with a minimum methylation
difference of 10% between the case and control groups and a Fisher’s multiple comparison
p-value < 0.01 were selected.
3. Results
3.1. Detection and Verification of an Episignature for MRXSA
The case samples included 6 males from three different families (Patients 1–4 from one
family, and Patients 5 and 6 from the two other families) (Table 1). We had two samples
from Patient 4 collected at ages 4 and 28 years. We used the sample from 28 years old
(sample A) for probe selection and training unsupervised and supervised models, and
the sample from 4 years old (sample B) as a testing sample. Patients 1–4 have the same
FAM50A variant, c.764A>G; p.Asp255Gly, and Patients 5 and 6 have variants c.761A>G;
p.Glu254Gly and c.763G>A; p.Asp255Asn, respectively. All the variants were classified as
pathogenic or likely pathogenic, according to the American College of Medical Genetics
(ACMG) guidelines. Variants of all patients, except for Patients 5 and 6, were inherited [21].
Table 1. Clinical and genetic information of the patients.
Patient

Kindred

Age

FAM50A Variant

Clinical Features

1

8100

62

c.764A>G;
p.Asp255Gly
inherited

Global developmental delay (GDD), glaucoma,
cataracts, short stature, speech problems, and
craniofacial anomalies

2

8100

50

c.764A>G;
p.Asp255Gly
inherited

Short stature, dysmorphic facial features, and a
left inguinal hernia

3

8100

45

c.764A>G;
p.Asp255Gly
inherited

GDD, speech problems, seizures, short stature,
craniofacial anomalies, glaucoma, and small
hands and feet

4

8100

28

c.764A>G;
p.Asp255Gly
inherited

GDD, dysmorphic facial features, strabismus, and
small feet

5

9656

10

c.761A>G;
p.Glu254Gly
de novo

GDD, strabismus, short stature, and dysmorphic
facial features

6

9677

26

c.763G>A;
p.Asp255Asn
de novo

GDD, dysmorphic facial features, and exotropia

Patient 1 last underwent a clinical examination at the age 62 and was institutionalized
since he was 24. He had seizures in infancy, presented with global developmental delay
(GDD), and started walking at age 7. He developed bilateral open-angle glaucoma and
bilateral cataracts later in adulthood. He also had short stature, speech problems, and
craniofacial anomalies [20]. The clinical presentations of patient 2 included short stature,
dysmorphic facial features, and a left inguinal hernia [20]. Patient 3 manifested GDD,
speech problems, seizures, short stature, craniofacial anomalies, glaucoma, and small
hands and feet [20]. Patient 4 had clinical features including GDD, dysmorphic facial
features, strabismus, and small feet [21]. More detailed clinical information of this patient
at different ages can be found in [20,21]. Patient 5 presented with GDD, dysmorphic
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For the purpose of classifying case and control samples more accurately, we constructed a binary SVM classifier with a linear kernel, using the selected probes (see the
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details in [19]). For each sample, the classifier creates a methylation variant probability
(MVP) score between 0 and 1. A sample is identified as having a methylation pattern
similar to the signature detected for the syndrome if the MVP score is near 1, and it is
indicated as having a methylation behavior similar to controls otherwise.
First, we only used samples from controls and samples from individuals with MRXSA for
training the model, and supplied over 1000 control subjects and cases of 38 other constitutional
disorders with episignatures from the EKD [19] (Table 2) into the model in order to assess
the specificity of our classifier. The classifier showed a high sensitivity for MRXSA, with
all samples scoring high on the MVP axis (Figure 4). The specificity, defined as the MVP
score >0.5 was over 99%, with 5 samples from other disease cohorts and controls (totaling
>1000 samples) scoring above that cut-off. Three of those cases are from the cohort of patients
with Chr5q35-qter duplication and a clinical diagnosis of Hunter McAlpine craniosynostosis
syndrome, suggesting level of similarity in the corresponding episignature.
Table 2. List of syndromes with a defined episignature, used for training a more accurate SVM.
Syndrome

Syndrome
Abbreviation

Underlying Gene/Location

Phenotype MIM Number

Signature Published

Cerebellar ataxia,
deafness, and narcolepsy,
autosomal dominant

ADCADN

DNMT1

604121

Yes [4,8,19,27]

Alpha-thalassemia mental
retardation syndrome

ATRX

ATRX

301040

Yes [4,7,8,19]

Autism, susceptibility to,
18

AUTS18

CHD8

615032

Yes [19,28]

BAFopathies: Coffin–Siris
1–4 (CSS1–4) and
Nicolaides-Baraitser
(NCBRS) syndromes

BAFopathy

ARID1A, ARID1B,
SMARCB1, SMARCA4,
SMARCA2

614607, 135900, 614609,
614608, 601358

Yes [4,17,19]

Börjeson-ForssmanLehmann
syndrome

BFLS

PHF6

301900

Yes [19]

Blepharophimosis
intellectual disability
syndrome

BIS

SMARCA2

NA

Yes [29]

Cornelia de Lange
syndrome 1–4

CdLS

NIPBL, RAD21, SMC3, SMC1A

122470, 614701, 610759,
300590

Yes [4,19]

CHARGE syndrome

CHARGE

CHD7

214800

Yes [4,8,9,19]

Down syndrome

Down

Chr21 trisomy

190685

Yes [4,19,30]

Chr7q11.23 duplication
syndrome

Dup7

Chr7q11.23
Duplication

609757

Yes [4,19,31]

Epileptic encephalopathy,
childhood-onset

EEOC

CHD2

615369

Yes [19]

Floating-Harbor
syndrome

FLHS

SRCAP

136140

Yes [4,8,15,19]

Genitopatellar syndrome

GTPTS

KAT6B

606170

Yes [4,8,19]

Hunter McAlpine
craniosynostosis
syndrome

HMA

Chr5q35-qter duplication
involving NSD1

601379

Yes [19]

Helsmoortel-van der Aa
syndrome (ADNP
syndrome [Central])

HVDAS_C

ADNP (c.2000-2340)

615873

Yes [4,19]

Helsmoortel-van der Aa
syndrome (ADNP
syndrome [Terminal])

HVDAS_T

ADNP (outside c.2000-2340)

615873

Yes [4,19]
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Table 2. Cont.
Syndrome

Syndrome
Abbreviation

Underlying Gene/Location

Phenotype MIM Number

Signature Published

Immunodeficiencycentromeric
instability-facial
anomalies syndrome 1

ICF1

DNMT3B

242860

Yes [19]

Immunodeficiencycentromeric
instability-facial anomalies
syndrome 2–4

ICF2-4

CDCA7, ZBTB24,
HELLS

614069, 616910, 616911

Yes [19]

Kabuki syndrome 1 and 2

Kabuki

KMT2D, KDM6A

147920, 300867

Yes [4,8,9,19,32]

Koolen de Vries syndrome

KDVS

KANSL1

610443

Yes [19]

Kleefstra syndrome 1

Kleefstra1

EHMT1

610253

Yes [19]

Mental retardation,
autosomal dominant 23

MRD23

SETD5

615761

No

Mental retardation,
autosomal dominant 51

MRD51

KMT5B

617788

Yes [19]

Mental retardation,
X-linked 93

MRX93

BRWD3

300659

Yes [19]

Mental retardation,
X-linked 97

MRX97

ZNF711

300803

Yes [19]

Mental retardation,
X-linked, syndromic,
Claes-Jensen type

MRXSCJ

KDM5C

300534

Yes [4,8,11,19]

Mental retardation,
X-linked syndromic,
Nascimento-type

MRXSN

UBE2A

300860

Yes [19]

Mental retardation,
X-linked, SnyderRobinson type

MRXSSR

SMS

309583

Yes [19]

PRC2: Cohen-Gibson
syndrome (COGIS) and
Weaver syndrome (WVS)

PRC2

EED, EZH2

617561, 277590

No

Rahman syndrome

RMNS

HIST1H1E

617537

Yes [19,33]

Rubinstein-Taybi
syndrome 1 and 2

RSTS

CREBBP, EP300

180849, 613684

Yes [19]

Ohdo syndrome, SBBYS
variant

SBBYSS

KAT6B

603736

Yes [8,19]

SETD1B-related syndrome

SETD1B

SETD1B

N/A

Yes [34]

Sotos syndrome

Sotos

NSD1

117550

Yes [4,8,13,19]

Tatton-Brown-Rahman
syndrome

TBRS

DNMT3A

615879

Yes [19]

Wiedemann-Steiner
syndrome

WDSTS

KMT2A

605130

Yes [19]

Williams-Beuren
syndrome

WBS

Chr7q11.23 deletion

194050

Yes [4,19,31]

Wolf-Hirschhorn
syndrome

WHS

Chr4p16.3 deletion

194190

No
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model in order to assess the specificity of our classifier. The classifier showed a high sensitivity for MRXSA, with all samples scoring high on the MVP axis (Figure 4). The specificity, defined as the MVP score >0.5 was over 99%, with 5 samples from other disease
cohorts and controls (totaling >1000 samples) scoring above that cut-off. Three of those
cases are from the cohort of patients with Chr5q35-qter duplication and a clinical diagno9 of 13
sis of Hunter McAlpine craniosynostosis syndrome, suggesting level of similarity in the
corresponding episignature.
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Table 2. List of syndromes with a defined episignature, used for training a more accurate SVM.

3.2. Identification of the Regions of Differential Methylation
MIM
Signature
We used Syndrome
the detected MRXSA Underlying
episignature to searchPhenotype
for DMRs. We
identified
55 regions
Syndrome
Abbreviation
Number
Published
of differential
methylation (TableGene/Location
S1). A region on chromosome
22 with the largest
number
Cerebellar ataxia, deafness,
and
of significant CpGs overlapped CPT1B, which has a role in cardiac development [35], and
CHKB, with aADCADN
function in the formation
of skeletal muscles [36].
narcolepsy,
DNMT1
604121
Yes [4,8,19,27]
autosomal dominant
Alpha-thalassemia mental retardation
ATRX
ATRX
301040
Yes [4,7,8,19]
syndrome
Autism, susceptibility to, 18
AUTS18
CHD8
615032
Yes [19,28]
BAFopathies: Coffin–Siris 1–4 (CSS1–4)
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4. Discussion
Over 50 genes and more than 42 neurodevelopmental conditions are currently described
with associated DNA methylation signatures, also referred to as episignatures or EpiSigns
[19,37]. Many of the related genes have a regulatory role in the epigenetic machinery; such as
histone modification, DNA methylation, or chromatin remodeling. We and others have shown
the diagnostic utility of genome-wide DNA methylation analysis using peripheral blood
[9,13,19,34,38]. This method has been applied to assign a diagnosis to many of the ND/CAaffected subjects that remained unresolved by conventional testing [4,8,9,17–19,32–34]. This
approach has also been effective in deriving a correct genetic diagnosis in patients with
incorrect initial clinical diagnosis [4]. More recently, the test called EpiSign, was adapted as
the first genome-wide DNA methylation clinical test for patients with ND/CA which can
be used either as part of diagnostic assessment or for reclassification of previously detected
VUSs (https://genomediagnostics.amsterdamumc.nl/epigenetic-test/; https://www.ggc.
org/episign).
The intellectual developmental disorder, X-linked, syndromic, Armfield type (MRXSA)
was described in 1999, as an intellectual disability disorder that presents with features
including global developmental delay, short stature, seizure, craniofacial anomalies, and
ocular abnormalities such as glaucoma [20]. Missense variants in FAM50A were recently
reported as the causal variants of the disorder [21]. Here, based on DNA methylation
samples collected from peripheral blood of 6 patients from 3 families, we identified an
episignature specific to the syndrome.
DNA methylation episignatures vary in their genomic locations and the robustness or
the DNA methylation difference across different disorders. MRXSA episignature is of the
more robust type, enabling a discovery and validation of the highly sensitive and specific
signal in a relatively small number of patient samples. More detailed information about
the 175 selected probes are summarized in Table S2. In particular, the gene they are located
on has been indicated, some of them having a regulatory role in development (for instance,
CPT1B). Figure 4 illustrates full sensitivity and specificity of our model, where all case samples
received a very high MVP score and all control samples and individuals from the other 38
constitutional disorders received a score near zero. Notably, sample B from Patient 4 received
a low MVP score compared to the rest of MRXSA samples. This is probably because the
blood samples were extracted from the patient 24 years apart, and the methylation profile has
changed during this time. Alternatively, some of the contributing factors may be related to the
specimen quality and storage, and wet-lab sample processing effects. While it is an established
fact that DNA methylation patterns are amongst the most accurate biomarkers of the aging
process, this finding is also in line with our previous observations that a loss-of-function
mutations in NSD1, which causes another EpiSign disorder, Sotos syndrome, substantially
accelerates epigenetic aging [39]. One limitation of genome-wide methylation analysis for
Mendelian neurodevelopmental disorders is that these syndromes are generally very rare. We
expect that by increasing the number of samples and expanding the range and type of variants
we may uncover further sub-stratification of the DNA methylation profile of FAM50A, as we
have previously observed for conditions including Weaver syndrome (WVS) and Coffin–Siris
syndrome (CSS) [8,17,40].
In addition to a distinct genome wide episignature that can be used as a sensitive
diagnostic biomarker, we also identified 55 regions of differential methylation in patients
with FAM50A variants. The most significant region contained 17 CpG sites, overlapping
two genes on chromosome 22 (CHKB and CPT1B) with a role in pattern formation and development. Other genes with functions in regulation of developmental processes included
LIMS3, which has a role in neural tissue patterning and differentiation [41]; PRDM9, which
is involved in histone modification and hence, in regulating the epigenetic machinery [42];
and CACNA1C, which is associated with Timothy syndrome (TS), a rare neurodevelopmental disorder [43]. While methylation changes in these regions point to the possibility of the
associated pathophysiology, further functional and integrative genomics analysis would be
necessary to study the possible causation or correlation. Also, while the use of peripheral
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blood for discovery of episignatures makes these findings broadly applicable to routine
diagnostic testing of patients with rare disorders, to better understand the pathophysiology
of these epigenetic changes, it will be important to study other tissues most significantly
affected by the clinical symptoms, including neuronal tissues.
In conclusion, the discovery of the MRXSA DNA methylation episignature adds to
the list of Mendelian neurodevelopmental disorders with DNA methylation episignatures
that can be used for screening and diagnosis of patients with rare neurodevelopmental
conditions. Additional work focused on expanding the number of cases and variant types
across the FAM50A gene is necessary to further refine this episignature and assess possible
additional DNA methylation profiles associated with this disorder.
Supplementary Materials: The following are available online at https://www.mdpi.com/1422-006
7/22/3/1111/s1, Table S1: List of the differentially methylated regions, Table S2: List of the probes
selected as the most differentiating probes between the MRXSA samples and control samples, Table
S3: Methylation levels (β values) at the selected probes for the MRXSA samples and control samples.
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